Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Peripheral Nervous System Diseases 3Lymphoma 3Lymphoma, Large B-Cell, Diffuse 2Breast Neoplasms 2Wilms Tumor 1Vaso-Occlusive Crises 1Sarcoma 1Prostatic Neoplasms 1Pain 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive, Peripheral 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Mucositis 1Lymphoma, Non-Hodgkin 1Lymphoma, Extranodal NK-T-Cell 1Leukemia 1Kidney Neoplasms 1Esophagitis 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Anemia, Sickle Cell 1

Interventions

AP 1903 reagent 2voxelotor 1maltodextrin 1fludarabine phosphate 1Whole-Body Irradiation 1Peripheral Blood Stem Cell Transplantation 1Glutamine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anemia, Sickle Cell × Glutamine × Clear all
NCT01179217 2020-08-19

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

Emmaus Medical, Inc.

Phase 3 Completed
230 enrolled 19 charts 1 FDA
Classical hematology

Vaso-Occlusive Crises, Anemia, Sickle Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡